3.8 Article

The coronavirus disease 2019 and effect on liver function: a hidden and vital interaction beyond the respiratory system

期刊

REVIEWS AND RESEARCH IN MEDICAL MICROBIOLOGY
卷 33, 期 1, 页码 E161-E179

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MRM.0000000000000267

关键词

bilirubin; hepatitis; liver function test; prognosis; severe acute respiratory syndrome-related coronavirus 2; severe acute respiratory syndrome

向作者/读者索取更多资源

This study reviews the characteristics of liver markers in patients with COVID-19, aiming to improve clinical treatment and gain new insights. The virus may affect liver cells and result in abnormal liver function markers. Further investigations are needed to understand the manifestations of COVID-19 in patients with chronic liver disease and to enhance clinical management and preventive measures.
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) emerged in December 2019 in Wuhan province, China. SARS-CoV-2 causes coronavirus disease 2019 (COVID-19). Angiotensin-converting enzyme 2 (ACE2) has an essential role as a receptor in the entry of the SARS-CoV-2 into the host cells. It has been declared, ACE2 expresses in the lungs, heart, kidneys, placenta, and liver. This study reviews the liver's markers' characteristics in patients with COVID-19 to achieve novel insights in improving clinical treatment. Liver disease and chronic kidney disease patients are susceptible to COVID-19. There is limited information about the effects of SARS-COV-2 on patients with preexisting liver associated disorders, including chronic hepatitis B virus or hepatitis C virus, primary biliary cirrhosis, nonalcoholic fatty liver disease, and more are yet to be understood. By considering conducted studies in this manner since ACE2 receptors, which are the primary receptors for SRAS-CoV-2, exist on the liver and lungs, heart, kidneys, and placenta, SRAS-CoV-2 can infect liver cells too. Consequently, this infection will have resulted in liver function tests' escalated levels and total bilirubin as biochemical biomarkers. Further investigations need to be done to point out the hepatic manifestations of COVID-19's infected patients with chronic liver disease and improve clinical management and more stringent preventive measures for this type of infected patients. Copyright (C) 2021 Wolters Kluwer Health, Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据